Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Door OMF gefinancierd onderzoek: vervormbaarheid van rode bloedcellen bij ME/CVS

In deze #OMFScienceWednesday presenteren we een nieuw door OMF gefinancierd project om de ‘vervormbaarheid’ van rode bloedcellen te evalueren als een potentiële biomarker voor ME/CVS.

Rode bloedcellen (RBCs) zijn de meest voorkomende cellen in het bloed. Hun hoofdrol is om zuurstof en kooldioxide in het bloed te transporteren, en deze rol hangt gedeeltelijk af van hun ‘vervormbaarheid’/elasticiteit terwijl ze door kleine bloedvaten stromen. Veranderingen in RBC-vervormbaarheid zijn in verband gebracht met ontstekingen en ziektes zoals sepsis, en sommige studies laten vermoeden dat RBC-schade voorkomt bij ME/CVS. Deze waarnemingen hebben samen met nieuwe beschikbare technologie voor het meten van RBC-vervormbaarheid het team van Dr. Ron Davis in Stanford en hun medewerkers aan de San Jose State University ertoe aangezet om RBC-vervormbaarheid bij ME/CVS te onderzoeken.

In sommige zeer vroege door dit team gegenereerde gegevens zijn er aanwijzingen dat de RBC-vervormbaarheid bij sommige ME/CVS-patiënten is verminderd. De RBCs bij ME/CVS die tot nu toe zijn getest, lijken volgens de testen met deze nieuwe technologie langzamer te bewegen en minder langwerpig te zijn dan bij gezonde controles. Wij financieren een project om deze bevindingen bij meer patiënten te bevestigen en om RBCs te bestuderen met behulp van aanvullende methoden, waaronder verschillende soorten geavanceerde microscopie, om beter te begrijpen waardoor deze verschillen bestaan.

Als deze experimenten succesvol zijn, kunnen zij tot een biomarker voor ME/CVS leiden die kan helpen bij de diagnose en het eventueel vinden van nieuwe behandelingen!

Blijf afgestemd voor meer nieuws.

Leer meer over RBCs in deze video van de Khan Academy:

https://www.youtube.com/watch?v=fLKOBQ6cZHA

OMF bedankt team Dutch US voor de vertaling

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo